Ascletis Approved to Start China Trials of FXR Agonist for Hepatitis B

Hangzhou 's Ascletis Pharma was approved to conduct trials of ASC42 in patients with chronic hepatitis B (CHB). ASC42 is a novel oral farnesoid X receptor (FXR) agonist that Ascletis developed in-house. In two pre-clinical tests, ASC42 significantly inhibited serum hepatitis B surface antigen (HBsAg) and HBV pregenomic RNA (pgRNA). Ascletis believes the candidate has potential to cure CHB. Previously, ASC42 was approved in China to treat NASH. More details.... Stock Symbol: (HK: 1672) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.